ALK and non-small cell lung carcinoma: Alectinib, brigatinib, and lorlatinib (second and third-generation ALK inhibitors) showed superior progression-free survival (PFS) and safety compared with crizotinib in the primary treatment of ALK-positive NSCLC in phase III trials [4,5,6].